pharma news

News

AbbVie's ovarian cancer drug Elahere gets NHS green light

AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.

News

White jigsaw pieces on a yellow background

Lilly strikes $1.9bn kidney disease alliance with Ascidian

In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.

News

ASCO26: Celcuity punished as trial disappoints investors

Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.

News

FDA prior knowledge guide seeks to speed cell, gene therapy

The FDA has laid out a framework to use 'prior knowledge' on manufacturing, non-clinical, and clinical data to support cell and gene therapy filings.

News

ASCO26: In vivo CAR-Ts in the spotlight

Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.

News

ASCO26: After negative adcomm, AZ builds case for oral SERD

AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.

AbbVie's ovarian cancer drug Elahere gets NHS green light

Lilly strikes $1.9bn kidney disease alliance with Ascidian

ASCO26: Celcuity punished as trial disappoints investors

FDA prior knowledge guide seeks to speed cell, gene therapy

ASCO26: In vivo CAR-Ts in the spotlight

ASCO26: After negative adcomm, AZ builds case for oral SERD

As patents expire, fampridine is cleared for NHS use in MS

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks